Structural features underlying the activity of benzimidazole derivatives that target phosphopeptide recognition by the tandem BRCT domain of the BRCA1 protein
V. Kurdekar, S. Giridharan, S. Jasti, M. B. Nijaguna, J. Periyasamy, S. Boggaram, K. Bharatham, V. Potluri, A. V. Shivange, G. Sadasivam, M. Padigaru, A. R. Venkitaraman
This paper identifies structural features of Bractoppin, a benzimidazole inhibitor of BRCA1 tBRCT phosphopeptide recognition, through chemical modifications and biochemical assays.
bioRxiv · Feb 20, 2019 · PreprintCancer Biology